University of Southern California Orthopaedic Surgery Associates, Keck School of Medicine, 1520 San Pablo Street, Suite 2000, Los Angeles, CA 90033. E-mail address:
OrthoIndy, 5255 East Stop 11 Road, Suite 300, Indianapolis, IN 46237.
J Bone Joint Surg Am. 2014 Jan 15;96(2):90-8. doi: 10.2106/JBJS.M.00058.
There are limited treatment options for tissue restoration and the prevention of degenerative changes in the knee. Stem cells have been a focus of intense preclinical research into tissue regeneration but limited clinical investigation. In a randomized, double-blind, controlled study, the safety of the intra-articular injection of human mesenchymal stem cells into the knee, the ability of mesenchymal stem cells to promote meniscus regeneration following partial meniscectomy, and the effects of mesenchymal stem cells on osteoarthritic changes in the knee were investigated.
A total of fifty-five patients at seven institutions underwent a partial medial meniscectomy. A single superolateral knee injection was given within seven to ten days after the meniscectomy. Patients were randomized to one of three treatment groups: Group A, in which patients received an injection of 50 × 10⁶ allogeneic mesenchymal stem cells; Group B, 150 × 10⁶ allogeneic mesenchymal stem cells; and the control group, a sodium hyaluronate (hyaluronic acid/hyaluronan) vehicle control. Patients were followed to evaluate safety, meniscus regeneration, the overall condition of the knee joint, and clinical outcomes at intervals through two years. Evaluations included sequential magnetic resonance imaging (MRI).
No ectopic tissue formation or clinically important safety issues were identified. There was significantly increased meniscal volume (defined a priori as a 15% threshold) determined by quantitative MRI in 24% of patients in Group A and 6% in Group B at twelve months post meniscectomy (p = 0.022). No patients in the control group met the 15% threshold for increased meniscal volume. Patients with osteoarthritic changes who received mesenchymal stem cells experienced a significant reduction in pain compared with those who received the control, on the basis of visual analog scale assessments.
There was evidence of meniscus regeneration and improvement in knee pain following treatment with allogeneic human mesenchymal stem cells. These results support the study of human mesenchymal stem cells for the apparent knee-tissue regeneration and protective effects.
目前针对膝关节组织修复和退行性改变的治疗方法有限。干细胞一直是组织再生的临床前研究热点,但临床研究有限。在一项随机、双盲、对照研究中,研究了关节内注射人骨髓间充质干细胞治疗膝关节的安全性、骨髓间充质干细胞促进半月板部分切除后再生的能力,以及骨髓间充质干细胞对膝关节骨关节炎变化的影响。
共有 55 名患者在 7 家机构接受了内侧半月板部分切除术。在半月板切除后 7 至 10 天内进行单次膝关节外侧上注射。患者随机分为三组:A 组,注射 50×106 个同种异体间充质干细胞;B 组,注射 150×106 个同种异体间充质干细胞;对照组,透明质酸钠(透明质酸/透明质酸)载体对照。通过两年的时间间隔,对患者进行随访,以评估安全性、半月板再生、膝关节整体状况和临床结果。评估包括连续磁共振成像(MRI)。
未发现异位组织形成或临床上重要的安全性问题。定量 MRI 显示,在半月板切除后 12 个月时,A 组 24%的患者和 B 组 6%的患者半月板体积显著增加(预先定义为 15%的阈值)(p=0.022)。对照组没有患者的半月板体积增加达到 15%的阈值。接受间充质干细胞治疗的骨关节炎患者的疼痛评分明显低于接受对照组治疗的患者,基于视觉模拟评分。
同种异体人骨髓间充质干细胞治疗后有半月板再生和膝关节疼痛改善的证据。这些结果支持对人骨髓间充质干细胞进行研究,以实现明显的膝关节组织再生和保护作用。